Review
Cell Biology
Yang Shao, Jing Kong, Hanzi Xu, Xiaoli Wu, YuePeng Cao, Weijian Li, Jing Han, Dake Li, Kaipeng Xie, Jiangping Wu
Summary: Our study included 476 ovarian cancer patients and 385 controls from eight eligible studies. The association between OPCML methylation and ovarian cancer risk was significant in various subgroups, and the findings were further validated by analyzing GEO and TCGA datasets. OPCML methylation was found to be related to advanced cancer stage and poorly differentiated grade, and specific CpG sites in the OPCML promoter region were significantly higher in cancer tissues compared to normal tissues. However, no associations were observed with clinicopathological parameters and overall survival based on TCGA ovarian cancer data. Overall, our findings support the link between OPCML methylation and increased ovarian cancer risk.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Multidisciplinary Sciences
Buze Chen, Xiaojuan Ding, Ailing Wan, Xin Qi, Xiaoman Lin, Haihong Wang, Wenyu Mu, Gang Wang, Junnian Zheng
Summary: TLX2 plays an important role in multiple tumors and its abnormal expression is associated with a poor overall survival rate in several cancer types. The most common type of alteration in TLX2 is amplification, and it co-occurs with alterations in other genes. TLX2 has high methylation levels in various tumors. Its expression is related to immune infiltration, immune checkpoint genes, and chemoresistance.
SCIENTIFIC REPORTS
(2023)
Article
Medicine, Research & Experimental
Donghyun D. Lee, Martin Komosa, Sumedha Sudhaman, Ricardo Leao, Cindy H. Zhang, Joana D. Apolonio, Thomas Hermanns, Peter J. Wild, Helmut Klocker, Farshad Nassiri, Gelareh Zadeh, Bill H. Diplas, Hai Yan, Steven Gallinger, Trevor J. Pugh, Vijay Ramaswamy, Michael D. Taylor, Pedro Castelo-Branco, Nuno Miguel Nunes, Uri Tabori
Summary: The research found that allele-specific DNA methylation within the TERT promoter plays a significant regulatory role in cancer, especially more common in adult cancers and enriched in tumors with TERT promoter mutations. This allele-specific DNA methylation is essential for the regulation of TERT expression in cancer.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Oncology
Per E. Lonning, Oleksii Nikolaienko, Kathy Pan, Allison W. Kurian, Hans P. Eikesdal, Mary Pettinger, Garnet L. Anderson, Ross L. Prentice, Rowan T. Chlebowski, Stian Knappskog
Summary: This study found a significant association between constitutional normal tissue BRCA1 promoter methylation and the risk of developing triple-negative breast cancer (TNBC) and high-grade serous ovarian cancer (HGSOC).
Review
Oncology
Soudeh Ghafouri-Fard, Tayyebeh Khoshbakht, Bashdar Mahmud Hussen, Mohammad Taheri, Majid Samsami
Summary: Circular RNAs (circRNAs) play a crucial role in the evolution and progression of ovarian cancer, serving as potential tumor markers and regulators of cancer cell metastasis and chemoresistance.
CANCER CELL INTERNATIONAL
(2022)
Article
Oncology
Chih-Ming Ho, Ting-Lin Yen, Tsai -Yen Chien, Shih-Hung Huang
Summary: CpG-island methylation plays a role in ovarian cancer progression and is associated with survival outcomes. Differential promoter methylation of tumor suppressor genes (TSGs) was observed, with RASSF1A hypomethylation and increased aggressiveness in mesenchymal-like OCSPCs. Overexpression of CCND2 and CDKN2B reduced the aggressiveness of mesenchymal-like OCSPCs and may serve as potential therapeutic targets for EOC.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Biotechnology & Applied Microbiology
Yang Lu, Qiang Cao, Yue Yu, Yazhou Sun, Xuan Jiang, Xin Li
Summary: This study reveals that the decrease in H3K4me1 levels coincides with DNA hypermethylation at promoter CGIs in various cancers. Removal of DNA hypermethylation leads to an increase in H3K4me1, especially at promoter CGIs of bivalent genes. Additionally, it is found that the demethylase LSD1 regulates the expression of the bivalent gene OVOL2, promoting tumorigenesis. Knockdown of OVOL2 in LSD1 knockout HCT116 cells restores the cancer cell phenotype.
Article
Oncology
Sung Ae Park, Nanae Masunaga, Naofumi Kagara, Yasuyo Ohi, Naomi Gondo, Kaori Abe, Tetsuhiro Yoshinami, Yoshiaki Sota, Tomohiro Miyake, Tomonori Tanei, Masafumi Shimoda, Yasuaki Sagara, Kenzo Shimazu
Summary: The restriction enzyme-based digital methylation-specific polymerase chain reaction (RE-dMSP) assay is a useful tool for diagnosing sentinel lymph node (SN) metastasis in breast cancer patients. It has high concordance with one-step nucleic acid amplification (OSNA) and can detect tumor-derived DNA with higher sensitivity. However, RE-dMSP showed certain discordance with OSNA and critically depended on the absence or heterogeneity of DNA methylation in breast tumors.
Article
Oncology
Chiara Herzog, Allison Jones, Iona Evans, Daniel Reisel, Adeola Olaitan, Konstantinos Doufekas, Nicola Macdonald, Angelique Floeter Radestad, Kristina Gemzell-Danielsson, Michal Zikan, David Cibula, Lukas Dostalek, Tobias Paprotka, Andreas Leimbach, Markus Schmitt, Andy Ryan, Aleksandra Gentry-Maharaj, Sophia Apostolidou, Adam N. Rosenthal, Usha Menon, Martin Widschwendter
Summary: Analysis of cell-free DNA methylation (cfDNAme) can aid in the early detection of ovarian cancers and potentially reduce mortality. Combining cfDNAme with CA125 can improve sensitivity for high-risk cancers. Despite technical limitations, ovarian cancer can be detected in samples taken within 1 year before diagnosis.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Pathology
Konstantinos Paschidis, Alexandros Zougros, Ilenia Chatziandreou, Spyridon Tsikalakis, Penelope Korkolopoulou, Nikolaos Kavantzas, Angelica A. Saetta
Summary: This study found that aberrant promoter methylation of RASSF1A and APC genes was frequently observed in non-small cell lung cancer, while methylation of MGMT, AXIN2, and DACT1 genes was less common. Concurrent methylation of at least two genes was observed in 55% of cases. Associations were found between methylation status of genes and clinicopathological features such as smoking status, tumor metastasis, and TTF1 expression.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Biochemistry & Molecular Biology
Lei Zhao, Xiaohong Wu, Junnian Zheng, Dong Dong
Summary: In this study, an efficient workflow LCM-mu WGBS was introduced to profile the DNA methylome of circulating tumor cells from lung cancer patients. A unique DNA methylation signature of CTCs distinct from primary lung cancer tissues was identified, with promoter hypermethylation of epithelial genes as a hallmark of stable epithelial-mesenchymal transition. Furthermore, CTCs may exhibit a stemness-related feature during dissemination and metastasis, providing potential noninvasive CTC DNA methylation biomarkers for clinical diagnosis.
Article
Oncology
Yeh Wang, Peng Huang, Brant G. Wang, Tricia Murdock, Leslie Cope, Fang -Chi Hsu, Tian -Li Wang, Ie-Ming Shih
Summary: By analyzing the precursor stage and cancer tissue of high-grade serous carcinoma (HGSC) in the ovary, researchers have identified the role of IGFBP2 in driving tumor initiation, providing new insights into ovarian cancer development.
Review
Developmental Biology
Kajal Rawat, Arushi Sandhu, Vipasha Gautam, Pradip Kumar Saha, Lekha Saha
Summary: Polycystic ovary syndrome (PCOS) is associated with aberrant DNA methylation, but the underlying mechanism remains unknown. This review analyzed existing data and found conclusive evidence of epigenetic deregulation of specific genes in PCOS, which could be potential diagnostic biomarkers or targets for personalized therapy.
MOLECULAR HUMAN REPRODUCTION
(2022)
Review
Oncology
Richard Sean Lee, Kirti Sad, Dorelle V. Fawwal, Jennifer Marie Spangle
Summary: Breast cancer is a frequent and deadly disease in women, with histone-modifying enzymes playing a role in treatment response and patient outcomes. Epigenetic changes to chromatin affect the tumor environment and can be targeted for breast cancer treatment. Understanding these mechanisms may improve therapeutic interventions and patient outcomes.
Review
Oncology
Francesco Guida, Shayan Dioun, Anna Fagotti, Alexander Melamed, Adriano Grossi, Giovanni Scambia, Jason D. Wright, Ana I. Tergas
Summary: This study evaluates the clinical utility of tertiary cytoreductive surgery in recurrent ovarian cancer through a systematic review and meta-analysis. The results show that optimal tertiary cytoreductive surgery is associated with improved disease specific survival and overall survival compared to suboptimal tertiary cytoreductive surgery.
GYNECOLOGIC ONCOLOGY
(2022)
